Aetna Members: You may have received a letter stating that The Dermatology of Indiana is no longer in-network, this is NOT accurate information.
Please contact your insurance if you have any questions or concerns. We look forward to continuing to serve your dermatology needs.

2014

Actinic Keratosis
Sponsor: LEO Pharma
Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis
18 Years and Older
Phase: Phase 1-2
Start Date: May 2014
End Date: May 2015

Actinic Keratosis
Sponsor: DUSA Pharmaceuticals, Inc.
Safety and Efficacy Study of Photodynamic Therapy With Levulan Kerastick + Blue Light for Actinic Keratoses on the Upper Extremities
18 Years and Older
Phase: Phase 3
Start Date: May 2014
End Date: Mar 2015

Plaque Psoriasis
Sponsor: Coherus Biosciences, Inc | Baxalta US Inc.
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
18 Years and Older
Phase: Phase 3
Start Date: June 2014
End Date: May 2016

Actinic Keratosis
Sponsor: DUSA Pharmaceuticals, Inc.
Twelve Month Follow-Up of CP0108
18 Years and Older
Phase: Phase 3
Start Date: August 2014
End Date: April 2016

Psoriasis
Sponsor: Janssen Research & Development
A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab
18-99 Years Old
Phase: Phase 3
Start Date: October 2014
End Date: May 2016

Dermatitis, Atopic
Sponsor: Regeneron Pharmaceuticals | Sanofi
Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
18 Years and Older
Phase: Phase 3
Start Date: November 2014
End Date: January 2016

Psoriasis
Sponsor: Janssen Research & Development, LLC
A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment
18-99 Years Old
Phase: Phase 3
Start Date: November 2014
End Date: November 2018

Psoriasis
Sponsor: Janssen Research & Development, LLC
A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis
18-99 Years Old
Phase: Phase 3
Start Date: November 2014
End Date: September 2018